May 21 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine candidate to wait for efficacy data from ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Moderna's decision to withdraw ...

Vaccine maker Moderna, Inc. (MRNA) said on Wednesday that it has withdrawn its application to the U.S. Food and Drug Administration (FDA) for approval of its seasonal flu-COVID combination vaccine ...

Novavax said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a stand-alone flu vaccine, sending shares of the company down ...

Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval The most common solicited local adverse event for ...

Moderna Inc. said it has “voluntarily” withdrawn its application for regulatory approval for its combination COVID and flu shot for people 50 and over, a setback for the company. The Cambridge-based ...

Moderna has withdrawn its pending application for a combination vaccine for both the flu and Covid-19, saying it will resubmit later this year once it has more data. The maker of the Spikevax Covid-19 ...